Preclinical Modeling, Imaging & Testing

临床前建模、成像和测试核心：项目摘要/摘要 临床前建模、成像和测试核心(PMIT核心)是科赫研究所的关键共享资源 将发现癌症研究和基于工程的技术开发的优势结合在一起的使命 推进癌症诊疗工作。对这一努力至关重要的是体外和体内疾病模型，包括 细胞、器官和脊椎动物模型。这些被用来探索癌症基因在细胞生物学中的作用，调查 肿瘤发生、发展和转移的机制，药物反应和耐药性的评估，以及测试新药 肿瘤检测和药物输送的策略和设备。这些方法中的每一个都依赖于专业知识和 仪器，以促进疾病模型的生成以及通过成像和 对药物、纳米材料、疫苗和设备的反应。PMIT核心为科赫研究所的研究人员提供 在生产工程细胞和小鼠模型方面提供咨询意见、技术支持和/或培训；以及 为检测、表征和治疗提供广泛的成像、处理和分析资源 在动物模型中发现肿瘤。 在本期间，PMIT核心的使用量显著增加，现在有71%的CCSG成员 (代表所有三个计划)依赖核心的服务。为了支持这一需求，我们还扩展了几个 能力。这包括，对于疾病建模：基于CRISPR/Cas9的基因编辑能力，以及专门的细胞和 类有机物的产生和处理方法。我们还通过聘请MRI专家(AS)扩展了成像能力 在上一次竞争性续签中建议)，收购PET/CT仪器(使用一次性机构资金)， 以及雇用一名PET/CT技术助理(短期机构资助)。因此，这种共享资源是必不可少的 为科赫研究所任务的成功干杯。 在接下来的一段时间里，PMIT核心将继续提供广泛的疾病建模、动物成像和 临床前试验服务，以支持中心成员的研究计划。我们将升级超声波和 MicroCT仪器(来自机构来源的资金)，并获得以下专业知识和计算能力 支持在高通量数据分析中使用机器学习算法(向CCSG申请资金 发展基金)。为了稳定工作人员工资并允许支持PET/CT技术助理，20.2% 要求增加PMIT核心CCSG预算。

Preclinical Modeling, Imaging & Testing Core: Project Summary/Abstract The Preclinical Modeling, Imaging & Testing Core (PMIT Core) is a critical Shared Resource in the Koch Institute’s mission of combining the strengths of discovery cancer research and engineering-based technology development to advance the diagnosis and treatment of cancer. Critical to this effort are in vitro and in vivo disease models, including cells, organoids and vertebrate models. These are used to probe the role of cancer genes in cell biology, investigate the mechanisms of tumor development, progression and metastasis, evaluate drug response and resistance, and test novel strategies and devices for tumor detection and drug delivery. Each of these approaches relies on expertise and instrumentation to facilitate the generation of disease models, as well as their characterization via imaging and in response to drugs, nanomaterials, vaccines and devices. The PMIT Core provides Koch Institute investigators with consultative advice, technical support and/or training in the production of engineered cells and mouse models, and provides extensive imaging, husbandry and analytic resources for detection, characterization and therapeutic treatment of tumors in animal models. During the current period, usage of the PMIT Core increased significantly and now 71% of CCSG Members (representing all three programs) rely on the Core’s services. To support this demand, we also expanded several capabilities. This includes, for disease modeling: CRISPR/Cas9-based gene editing capabilities, and specialized cell and organoid generation and manipulation methods. We also expanded imaging capabilities by hiring an MRI Specialist (as recommended in the previous competing renewal), acquiring PET/CT instrumentation (with one-time Institutional funds), and hiring a PET/CT Technical Associate (with short-term Institutional funding). Thus, this Shared Resource is essential to the success of the Koch Institute mission. In the upcoming period, the PMIT Core will continue to offer a wide range of disease modeling, animal imaging and preclinical testing services to support the research programs of Center Members. We will upgrade ultrasound and microCT instrumentation (with funds from Institutional sources), and acquire expertise and computing capabilities that enable use of machine learning algorithms in high throughput data analysis (funding requested from CCSG Developmental Funds). To stabilize staff salaries and allow support of the PET/CT Technical Associate, a 20.2% increase in the PMIT Core CCSG budget is requested.